SCHEMBL23923981

SCHEMBL23923981

S=C(Nc1cccc2cnccc12)OC1CNCC1c1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 14/20 0.47
MAPT P10636 11/20 0.47
KDM4E B2RXH2 8/20 0.47
SMN1; SMN2 Q16637 7/20 0.47
HTT P42858 6/20 0.47
NPC1 O15118 1/20 0.47
GALR3 O60755 1/20 0.47
NR2F2 P24468 1/20 0.47
LMNA P02545 6/20 0.47
NSD2 O96028 1/20 0.47
KMT2A Q03164 5/20 0.47
MEN1 O00255 3/20 0.46
BLM P54132 2/20 0.46
MAPK1 P28482 1/20 0.46
TRPV1 Q8NER1 3/20 0.44
THRB P10828 1/20 0.43
HPGD P15428 1/20 0.43
CASP3 P42574 1/20 0.43
SENP8 Q96LD8 1/20 0.43
SENP7 Q9BQF6 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23951804 1.00 ALDH1A1 (0.47) ALDH1A1MAPTKDM4ESMN1; SMN2HTT
SCHEMBL23951333 1.00 ALDH1A1 (0.47) ALDH1A1MAPTKDM4ESMN1; SMN2HTT
SCHEMBL29900607 1.00 ALDH1A1 (0.47) ALDH1A1MAPTKDM4ESMN1; SMN2HTT
SCHEMBL23924173 0.88 TRPV1 (0.49) ALDH1A1MAPTKDM4ESMN1; SMN2HTT
SCHEMBL23951601 0.88 TRPV1 (0.49) ALDH1A1MAPTKDM4ESMN1; SMN2HTT
SCHEMBL23924176 0.88 TRPV1 (0.49) ALDH1A1MAPTKDM4ESMN1; SMN2HTT
SCHEMBL23924256 0.81 KMT2A (0.48) ALDH1A1MAPTKDM4ESMN1; SMN2HTT
SCHEMBL23924009 0.81 KMT2A (0.48) ALDH1A1MAPTKDM4ESMN1; SMN2HTT
SCHEMBL23924011 0.81 KMT2A (0.48) ALDH1A1MAPTKDM4ESMN1; SMN2HTT
SCHEMBL23951372 0.80 ALDH1A1 (0.53) ALDH1A1MAPTKDM4ESMN1; SMN2HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220213061-A9 HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 TES PHARMA S.R.L. (IT) 2022-07-07 US claimed
US-20210323942-A1 HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 TES PHARMA S R L (IT) 2021-10-21 US claimed
EP-4110758-A1 HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 Tes Pharma S.r.l. (IT) 2023-01-04 EP disclosed
US-20220213061-A9 HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 TES PHARMA S.R.L. (IT) 2022-07-07 US disclosed
US-20220213061-A9 HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 TES PHARMA S.R.L. (IT) 2022-07-07 US disclosed
US-20210323942-A1 HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 TES PHARMA S R L (IT) 2021-10-21 US disclosed
US-20210323942-A1 HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 TES PHARMA S R L (IT) 2021-10-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220213061-A9 HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 NR2E3, NR2F2, NR2C2 ALDH1A1 2328/4885MAPT 2615/4885KDM4E 2961/4885
US-20210323942-A1 HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 NR2E3, NR2F2, NR2C2 ALDH1A1 2328/4885MAPT 2615/4885KDM4E 2961/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.